The catcher in the gut: Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity

The ever-increasing burden of obesity, type 2 diabetes mellitus (T2DM) and related comorbidities is demanding a better pathophysiological understanding as well as new treatment options. Incretin based therapies are already available while the recent Food and Drug Administration (FDA) approval of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lempesis, Ioannis G., Liu, Junli, Dalamaga, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747662/
https://www.ncbi.nlm.nih.gov/pubmed/36530219
http://dx.doi.org/10.1016/j.metop.2022.100220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747662/
https://www.ncbi.nlm.nih.gov/pubmed/36530219
http://dx.doi.org/10.1016/j.metop.2022.100220

Ejemplares similares